San Jose, California February 8, 2010 -- Hypertension is a state when the blood flows at levels above the normal pressure through the arteries, all through the day, resulting in the blood pressure reaching or exceeding 140/90 mmHg. An individual with hypertension experiences this level of blood pressure despite being composed and relaxed. The flow of blood pressure in the arteries generally increases when walls of the vessels harden and lose elasticity, are obstructed, or shrink in diameter.
The global market for anti-hypertensives is large and growing, driven by high blood pressure reaching epidemic proportions in both developed and developing countries. Despite the huge potential, the market remains more or less untapped. The market also faces challenges such as growing competition, and increased threat to branded drugs from generic variants. The anti-hypertensive drugs market is characterized by high extent of genericization and the lack of innovation on the research & development front.
Anti-hypertensive Drugs: A Global Strategic Business Report Europe and the United States dominate the world anti-hypertensive drugs market as stated by the new market research report on Anti-hypertensive drugs. The prevalence of hypertension is more in Europe than elsewhere in world, indicating hypertension is the primary cause of mortality, and one of the main causes of disability in Europe. With millions of suffers, the US also has high blood pressure is one of the leading factors for the risk of cardiovascular disease, and the leading cause of mortality in the country.
The US anti-hypertensive drugs market is characterized by availability of a large number of drugs (both branded and generic), patent expiry of leading drugs, and inadequate efforts towards research & development of new, innovative drugs. Most new drugs are combination of existing therapies, the last innovation being the development of renin inhibitors (marketed as Tekturna/Rasilez), which provide significant scope for therapeutic and commercial success. The leading class of drug, nevertheless, constitutes the angiotensin II blockers that provides improved efficiency and tolerability.
The market for Anti-hypertensive Drugs is characterized by the presence of large number of players, several of them offering generic anti-hypertensive products. Competition is restricted to the available branded products marketed by select pharmaceutical companies. Though several companies are involved in research and development, and the pipeline for new drug candidates is extensive, it does not boasts of any breakthrough compounds. Key players profiled in the report include AstraZeneca PLC, Bayer AG, Biovail Corporation, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Forest Laboratories, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-aventis, Solvay Pharmaceuticals SA, among others.
The report titled "Anti-hypertensive Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market dynamics, research & development, product introductions/approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Anti_Hypertensive_Drugs_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/
